文献速递神经肿瘤

组蛋白去乙酰化酶抑制剂SAHA通过靶向c-Myc/CCL1通路抑制胶质瘤干细胞中Treg细胞的作用并改善PD-L1阻断治疗

Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy.
PubMed 文献 · J Neurooncol · 2024-04-23

本研究在免疫健全的GBM颅内异种移植小鼠模型中探究SAHA对免疫抑制性Treg的作用机制。SAHA有效抑制肿瘤生长并显著延长总生存期,促进CD8+ T淋巴细胞浸润并抑制CD4+CD25+ Treg浸润,增强抗PD-L1免疫治疗。机制上SAHA通过抑制HDAC2抑制c-Myc与CCL1启动子的结合,阻断CCL1-CCR8相互作用,降低Treg活性并缓解肿瘤免疫抑制。

要点

  • SAHA在免疫健全GBM颅内异种移植小鼠模型中抑制肿瘤生长并显著延长总生存期。
  • SAHA促进CD8+ T淋巴细胞浸润、抑制CD4+CD25+ Treg浸润,并增强抗PD-L1免疫治疗。
  • SAHA通过抑制HDAC2阻断c-Myc与CCL1启动子结合,阻断CCL1-CCR8相互作用以降低Treg活性。

核心结论

  • SAHA抑制c-Myc与CCL1启动子结合并抑制CCL1转录,阻断CCL1-CCR8相互作用,降低Treg活性并缓解肿瘤免疫抑制。

研究设计与样本

  • 在免疫健全的GBM颅内植入异种移植小鼠模型中分析肿瘤浸润免疫细胞,采用免疫组化和流式细胞术检测。
  • 采用RT-qPCR评估mRNA表达,采用western blot、ELISA、免疫荧光和流式细胞术检测相关蛋白表达。
  • 采用双荧光素酶报告基因系统和染色质免疫沉淀验证c-Myc与CCL1启动子的关系。

主要发现

  • SAHA有效抑制免疫健全GBM颅内异种移植小鼠模型的肿瘤生长并显著延长总生存期。
  • SAHA促进CD8+ T淋巴细胞浸润,同时抑制CD4+CD25+ Treg浸润。
  • SAHA增强小鼠颅内异种移植瘤的抗PD-L1免疫治疗。
  • 机制上SAHA通过抑制HDAC2抑制c-Myc与CCL1启动子的结合。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A strong immunosuppressive tumor microenvironment (TME) represents the major barrier responsible for the failure of current immunotherapy approaches in treating Glioblastoma Multiforme (GBM). Within the TME, the regulatory T cells (Tregs) exert immunosuppressive effects on CD8+ T cell - mediated anti-cancer immune killing. Consequently, targeting and inhibiting their immunosuppressive function emerges as an effective therapeutic strategy for GBM. The present study aimed to investigate the mechanisms and effects of Suberanilohydroxamic Acid (SAHA), a histone deacetylase inhibitor, on immunosuppressive Tregs. METHODS: The tumor-infiltrating immune cells in the immunocompetent GBM intracranial implanted xenograft mouse model were analyzed by immunohistochemistry and flow cytometry techniques. The mRNA expressions were assessed through the RT-qPCR method, while the related protein expressions were determined using western blot, ELISA, immunofluorescence (IF), and flow cytometry techniques. The relationship between c-Myc and C-C motif Chemokine Ligand 1 (CCL1) promotor was validated through a dual-luciferase reporter assay system and chromatin immunoprecipitation. RESULTS: SAHA suppressed effectively tumor growth and extended significantly overall survival in the immunocompetent GBM intracranial xenograft mouse model. Additionally, it promoted the infiltration of CD8+ T lymphocytes while suppressed the infiltration of CD4+ CD25+ Tregs. Furthermore, SAHA enhanced anti-PD-L1 immune therapy in the intracranial xenograft of mice. Mechanistically, SAHA exerted its effects by inhibiting histone deacetylase 2 (HDAC2), thereby suppressing the binding between c-Myc and the CCL1 promotor. CONCLUSION: SAHA inhibited the binding of c-Myc with the CCL1 promoter and then suppressed the transcription of CCL1.Additionally, it effectively blocked the interplay of CCL1-CCR8, resulting in reduced activity of Tregs and alleviation of tumor immunosuppression.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Sun T, Liu B, Cai L, et al. Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy. J Neurooncol. 2024. PMID: 38652401. doi:10.1007/s11060-024-04689-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。